RxDoctor Payments DataLook up a doctor →

Stephanie Rutz, PA

Medical · Lafayette, CONPI 1558545004

Payments from drug & device makers

$29,261in general payments, 2019–2025

Across 546 payments — averaging $53.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$13K
  • Saluda Medical Americas, Inc.$5K
  • AbbVie$3K
  • Pfizer$2K
  • Abbott$1K
  • Medtronic$1K
  • plus $4K from 24 others

What the payments were for

  • Consulting fees$6752%
  • Speaking & faculty fees$11,65540%
  • Travel & lodging$1,7486%
  • Food & beverage$15,18252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,261 in reported general payments places this provider in the 95th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$145,557
Medicare patients
59
Services billed
15,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl62$38,637
Xtampza ErOxycodone Myristate45$37,594
Qudexy XrTopiramate11$9,855
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen146$7,012
Oxycodone Hcl228$5,248
Sumatriptan Succinate28$4,743
Morphine Sulfate ErMorphine Sulfate83$3,229
Fentanyl25$2,910
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen62$2,665
Gabapentin73$1,817
Tramadol Hcl70$915
Duloxetine Hcl40$902
Methocarbamol34$884
Hydromorphone Hcl39$832
Tramadol Hcl ErTramadol Hcl14$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$247$37,59445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 766 medical providers in Colorado.

Other medical in Lafayette

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →